RJA
AMAG

Raymond James & Associates’s AMAG Pharmaceuticals AMAG Stock Holding History

Raymond James & Associates’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-12,000
Closed -$294K – 3401
2016
Q3 		$294K Buy
+12,000
New +$300K ﹤0.01% 2639

Other funds holding AMAG

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James & Associates's AMAG Position: Q4 2016 in Review

Raymond James & Associates sold out of AMAG Pharmaceuticals (AMAG) in Q4 2016, closing a stake of 12,000 shares — an estimated $294K sold.

Raymond James & Associates first reported a position in AMAG in Q3 2016 and held it in 1 quarter. The position peaked at $294K in Q3 2016. 206 funds tracked by Wall St. Rank hold AMAG as of Q4 2016.

  • Raymond James & Associates reported no remaining AMAG Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Raymond James & Associates sold 12,000 AMAG Pharmaceuticals shares in Q4 2016, an estimated $294K.
  • Raymond James & Associates first reported a position in AMAG Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Raymond James & Associates's AMAG Pharmaceuticals position peaked at $294K in Q3 2016.
  • 206 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q4 2016.

Based on Raymond James & Associates's 13F filing for Q4 2016, filed 14 Feb 2017.